Evaluating the Efficacy of CPAP Therapy for the Treatment of Fatty Liver
Withdrawn before enrolling · Not applicable
Conditions studied: Non-alcoholic Fatty Liver Disease
In brief
We are doing this research study to evaluate whether continuous positive airway pressure (CPAP), a treatment for sleep apnea, will also help treat fatty liver disease. Sleep apnea is a disease where a person has interruptions in their breathing while they are sleep. This can lead to low oxygen levels in the blood. CPAP is a mask that delivers oxygen at high pressure to the lungs to prevent a decrease in blood oxygen levels. CPAP is a known treatment for sleep apnea.
Key facts
- Study ID
- NCT01849081
- Run by
- Massachusetts General Hospital
- People needed
- 0
- Starts
- 2019-03-01
- Expected to finish
- 2019-03-01
- Last updated by the study team
- 2020-10-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adults 18 years of age or older with a previous liver biopsy showing NASH and at least grade 2 steatosis
- Obstructive sleep apnea diagnosed by sleep study.
You may not qualify if…
- Other causes of chronic liver disease
- cirrhosis
- less than 33% steatosis identified on magnetic resonance spectroscopy (MRS)
- Alcohol use >2 units per day for women or >3 units per day for men
- Intolerance to or refusal of CPAP therapy
- overnight desaturation (more than 10% of the sleep time with oxygen desaturation below 85%)
- underlying sever sleepiness (Epworth scale more than 15)
- uncontrolled hypertension
- Severe heart failure (ejection fracture less than 30%)
- cardiac arrhythmias (atrial fibrillation or history of ventricular tachycardia)
- those who are commercial drivers
Where it is running
- Massachusetts General Hospital — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.